EUCTR2006-004639-31-ATActive, not recruitingNot Applicable
Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemonaive patients with NSCLC stage IB, II, and IIIA. - INN06
TAKO0 sitesStarted: November 16, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Histologically confirmed NSCLC; histology may include: large cell, squamous cell or adenocarcinoma but not small cell lung cancer
- •Anatomically and functionally resectable NSCLC stage IB (T2N0), stage II (T1-2 N1, T3 N0) or stage IIIA (T3 N1)
- •Measurable disease according to RESIST criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Evidence of brain metastases or other distand metastases equivalent to stage IV disease
- •History of prior malignancies, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix or other curatively treated cancer with no evidence of disease for at least five years
- •Other serious concomitant illnesses or medical conditions
- •Prior chemotherapy or immunotherapy for NSCLC
- •Prior surgery or radiotherapy for NSCLC
- •Concurrent treatment with other experimental drugs, unapproved medical procedures or other anticancer therapy
- •Concurrent continuous treatment with systemic steroids for antiemetic use, intermittent application is allowed
Investigators
Similar Trials
Recruiting
Not Applicable
A Multicenter phase II study of Docetaxel combined with Bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000009966Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University20
Completed
Phase 2
Multicenter phase II study of docetaxel/cisplatin/bevacizumab combination therapy in patients with advanced non-squamous non-small cell lung cancer (TORG1016)JPRN-UMIN000004368Thoracic Oncology Research Group47
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)EUCTR2005-005464-92-DESanofi-aventis groupe270